La transplantation d’hépatocytes représente une alternative à la transplantation hépatique pour le traitement de certaines maladies métaboliques dont l’hypercholestérolémie familiale. Les cellules souches embryonnaires (ES) et les cellules souches pluripotentes induites (iPS) humaines représentent de nouvelles sources de cellules hépatiques. Nous avons mis au point une approche de différenciation des cellules souches humaines en cellules hépatiques et généré ainsi des cellules dérivées de cellules iPS de patients atteints d’hypercholestérolémie familiale. / Hepatocyte transplantation represents an alternative to liver for the treatment of metabolic diseases including familial hypercholesterolaemia. Embryonic stem cells (ES) and induced pluripotent stem cells (iPS) represent new sources of hepatic cells. We have developed an approach to differentiate human stem cells into hepatic cells and thus we have generated hepatic cells derived from iPS of familial hypercholesterolaemia patients.

La thérapie cellulaire pourrait représenter une alternative à la transplantation hépatique dans certaines pathologies comme les maladies métaboliques sévères. Toutefois, la pénurie de donneurs d’organes implique la nécessité de trouver de nouvelles sources de cellules hépatiques comme les cellules souches pluripotentes qui peuvent être amplifiées extensivement et différenciées en tout type cellulaire. Les cellules souches embryonnaires humaines (hESC) et les cellules souches pluripotentes induites humaines (hiPSC) générées à partir des cellules somatiques de patients puis différenciées en hépatocytes représentent une source potentielle d’hépatocytes. Ces cellules permettent en outre d’envisager la transplantation d’hépatocytes autologues génétiquement modifiés comme alternative à la transplantation hépatique pour le traitement de certaines maladies génétiques du foie. L’hypercholestérolémie familiale (HF) est une maladie autosomale dominante due à des mutations dans le gène codant le Récepteur aux Low Density Lipoproteins (RLDL) qui est à l’origine d’un taux élevé de cholestérol sanguin de patients HF. Les patients homozygotes doivent épurer leur sérum par LDL-aphérèse en moyenne deux fois par mois dès le plus jeune âge pour éviter les infarctus mortels survenant dès l’enfance. Les hépatocytes différenciées à partir des iPSC de patients et leur correction in vitro, permettent d'évaluer la faisabilité de la transplantation d'hépatocytes autologues génétiquement modifiés pour le traitement de l’hypercholestérolémie familiale.Au cours du développement du foie, des hépatocytes et des cholangiocytes, les deux types de cellules épithéliales hépatiques, dérivent de progéniteurs hépatiques bipotents (les hépatoblastes). Bien que les cholangiocytes formant les canaux biliaires intrahépatiques ne représentent qu'une petite fraction de la population cellulaire totale du foie (3%), ces cellules régulent activement la composition de la bile par réabsorption des acides biliaires, un processus qui est important dans des maladies choléstatiques du foie. Dans la première partie de cette étude nous avons mis au point une approche de différenciation des cellules souches pluripotentes (hESC et hiPSC) en cholangiocytes fonctionnels. Ces cellules serviront à la modélisation des maladies génétiques touchant les cholangiocytes formant des canaux biliaires. Dans la deuxième partie, nous avons généré des iPSC spécifiques de patients HF (HF-iPSC), différenciées en hépatocytes et corrigé le défaut phénotypique par transfert lentiviral de l’ADNc codant le LDLR dans les HF-iPSC. / Cell therapy can be an alternative to liver transplantation in some cases such as severe metabolic diseases. However, the shortage of organ donors implies the need to find new sources of liver cells such as hepatocytes derived from pluripotent stem cells that can be amplified and differentiated extensively into any cell type. Human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) generated from somatic cells of patients and then differentiated into hepatocytes represent a potential source of transplantable hepatocytes. These cells now make it possible to consider the transplantation of genetically modified autologous hepatocytes as an alternative to liver transplantation for the treatment of genetic diseases of the liver.Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by mutations in the gene encoding the receptor for Low Density Lipoproteins (LDLR), which is the cause of high blood cholesterol in these patients. Homozygous patients should purify their serum LDL-apheresis on average twice a month starting at a young age to avoid fatal myocardial infarction occurring in childhood.Human hepatocytes differentiated from patient’s induced pluripotent stem cells (iPSCs) allow assessing the feasibility to transplant genetically modified autologous hepatocytes as treatment of familial hypercholesterolemia.During the liver development, hepatocytes and cholangiocytes, the two types of hepatic epithelial cells, derive from bipotent hepatic progenitors (hepatoblasts). Although cholangiocytes, forming intrahepatic bile ducts, represent a small fraction of the total liver cell population (3%), they actively regulate bile composition by secretion and reabsorption of bile acids, a process that is important in cholestatic liver diseases. In the first part of this study we developed an approach to differentiate pluripotent stem cells (hESC and hiPSC) into functional cholangiocytes. These cells could be used for the modeling of genetic biliary diseases. In the second part, we generated FH patient specific iPSCs (HF-iPSC), differentiated them into hepatocytes and tried to correct the disease phenotype by lentiviral introduction of LDLR cDNA cassette in HF-iPSC.

No description available.

The human heart has poor endogenous regeneration. If myocytes are lost due to injury, the myocardium is unable to restore its myocyte content and instead undergoes compensatory hypertrophy and remodeling. Cardiac tissue engineering aims to recreate and provide functional myocardium that replaces the injured myocardium. In this study, human engineered heart muscle (EHM) from cardiomyogenically differentiated human embryonic stem cells was generated. EHMs consisted of elongated, anisotropically organized cardiomyocyte bundles and responded “physiologically” to increasing calcium concentrations. To generate large myocardium capable of encompassing the ventricles, a novel process to systematically upscale the dimensions of engineered myocardium to a humanized Biological Ventricular Assisted Device (hBioVAD) was introduced. The hBioVADs formed a “pouch-like” myocardium at rabbit heart dimensions and were beating spontaneously. Further enhancement by biomimetic pulsatile loading generated “more mature” myocardium. Additional paracrine functionality was integrated by generating insulin-like growth factor-1 (IGF-1) secreting fibroblasts for tissue engineering applications. IGF-1 release induced higher levels of Akt phosphorylation and hypertrophy in cardiomyocytes resulting in increased force generation of EHM. Finally, feasibility of “paraBioVAD” (IGF-1 cell line and cardiomyocytes) implantation was demonstrated in a healthy rat model. Histological observations demonstrated engraftment on the heart and the presence of vascular structures. In conclusion, a humanized “paraBioVAD” technology for mechanic and paracrine heart support was developed. Future studies will assess its therapeutic utility in heart failure

Les cellules souches embryonnaires (cellules ES) sont pluripotentes et ont donc le potentiel de se différencier en cellules des trois feuillets embryonnaires, ainsi qu’en cellules de la lignée germinale. Ces propriétés en font un modèle pour l’étude des mécanismes de prolifération et de différenciation. Le facteur de transcription Lmx1b est impliqué dans la maintenance du phénotype différencié des neurones dopaminergiques mésencéphaliques. Et il a aussi été montré comme un facteur clef dans la différenciation et la maintenance des neurones sérotoninergiques du rhombencéphale générés dans les noyaux du Raphé. Dans ce travail, nous nous sommes intéressés aux capacités de Lmx1b d’influencer la différenciation des cellules ES de souris en neurones sérotoninergiques. La première stratégie adoptée a résulté en une expression ectopique stable de Lmx1b dans les cellules ES et leurs dérivés. Le niveau d’expression de Lmx1b a fortement influencé les capacités de différenciation neuronale des cellules. Puis, l’analyse de marqueurs de différenciation spécifiques a montré une augmentation de l’expression des marqueurs sérotoninergiques, au contraire des marqueurs dopaminergiques ou de neurones moteur. La seconde stratégie a consisté en une surexpression inductible de Lmx1b dans les précurseurs neuraux dérivés de cellules ES pour mimer l’expression physiologique de Lmx1b. Après induction, Lmx1b était bien exprimé dans les cellules durant toutes les étapes de différenciation neuronale. L’activation de l’expression de Lmx1b au stade des colonies neuroépithéliales a aussi résulté en une amélioration de la différenciation sérotoninergique. Les résultats de ce travail soulignent les capacités de Lmx1b à diriger la différenciation des précurseurs neuraux dérivés de cellules ES vers la voie sérotoninergique in vitro. / Pluripotent Embryonic Stem Cells (ESC) have the potential to develop into cells of the three germ layers and of the germ line. Therefore, they are used as a model to study the proliferation and differentiation mechanisms. The LIM homeodomain transcription factor Lmx1b is involved in the maintenance of the differentiated phenotype of midbrain dopaminergic neurons. And it has been also demonstrated to be a key factor in differentiation and maintenance of hindbrain serotonergic neurons generated in the Raphe Nuclei. Here, we explored the capacity of Lmx1b to direct differentiation of mouse ESC (mESC) into serotonergic neurons. In the first approach, stable ectopic expression of Lmx1b was achieved. First, the level of Lmx1b expression was found to strongly influence the capacity of mESC to accomplish neuronal differentiation. Then, analysis of lineage-specific differentiation markers showed an increase in serotonergic markers’ expression by contrast to dopaminergic or motor neurons markers. In the second approach, Lmx1b was over-expressed in mESC-derived neural precursors by an inducible system in order to mimic the physiological onset of Lmx1b expression. After induction, Lmx1b was found to be stably expressed throughout neuronal differentiation. Activation of Lmx1b expression in neuroepithelial colonies resulted in enhancement of serotonergic differentiation, consistently with the stable system results. The results of this work highlight the capacity of Lmx1b to promote the shift of mESC-derived neural precursors toward a serotonergic fate in vitro.

Mouse embryonic stem cells (mESCs) can be maintained in a proliferative and undifferentiated state over many passages (self-renewal) while retaining the potential to give rise to every cell type of the organism (pluripotency). Autocrine FGF4/Erk signalling has been identified as a major stimulus for fate decisions and lineage commitment in these cells. Recent findings on serum-free culture conditions with specific inhibitors (known as 2i) demonstrate that the inhibition of this pathway reduces transcription factor heterogeneity and is vital to maintain ground state pluripotency of mESCs. We suggest a novel mathematical model to explicitly integrate FGF4/Erk signalling into an interaction network of key pluripotency factors (namely Oct4, Sox2, Nanog and Rex1). The envisaged model allows to explore whether and how proposed mechanisms and feedback regulations can account for different expression patterns in mESC cultures. We demonstrate that an FGF4/Erk-mediated negative feedback is sufficient to induce molecular heterogeneity with respect to Nanog and Rex1 expression and thus critically regulates the propensity for differentiation and the loss of pluripotency. Furthermore, we compare simulation results on the transcription factor dynamics in different self-renewing states and during differentiation with experimental data on a Rex1GFPd2 reporter cell line using flow cytometry and qRT-PCR measurements. Concluding from our results we argue that interaction between FGF4/Erk signalling and Nanog expression qualifies as a key mechanism to manipulate mESC pluripotency. In particular, we infer that ground state pluripotency under 2i is achieved by shifting stable expression pattern of Nanog from a bistable into a monostable regulation impeding stochastic state transitions. Furthermore, we derive testable predictions on altering the degree of Nanog heterogeneity and on the frequency of state transitions in LIF/serum conditions to challenge our model assumptions.

Indiana University-Purdue University Indianapolis (IUPUI) / The inner ear contains specialized sensory epithelia that detect head movements, gravity and sound. Hearing loss and imbalance are primarily caused by degeneration of the mechanosensitive hair cells in sensory epithelia or the sensory neurons that connect the inner ear to the brain. The controlled derivation of inner ear sensory epithelia and neurons from pluripotent stem cells will be essential for generating in vitro models of inner ear disorders or developing cell-based therapies. Despite some recent success in deriving hair cells from mouse embryonic stem (ES) cells, it is currently unclear how to derive inner ear sensory cells in a fully defined and reproducible manner. Progress has likely been hindered by what is known about induction of the nonneural and preplacodal ectoderm, two critical precursors during inner ear development. The studies presented here report the step-wise differentiation of inner ear sensory epithelia from mouse ES cells in three-dimensional culture. We show that nonneural, preplacodal and pre-otic epithelia can be generated from ES cell aggregates by precise temporal control of BMP, TGFβ and FGF signaling, mimicking in vivo development. Later, in a self-guided process, vesicles containing supporting cells emerge from the presumptive otic epithelium and give rise to hair cells with stereocilia bundles and kinocilium. Remarkably, the vesicles developed into large cysts with sensory epithelia reminiscent of vestibular sense organs (i.e. the utricle, saccule and crista), which sense head movements and gravity in the animal. We have designated these stem cell-derived structures inner ear organoids. In addition, we discovered that sensory-like neurons develop alongside the organoids and form putative synapses with hair cells in a similar fashion to the hair cell-to-neuron circuit that forms in the developing embryo. Our data thus establish a novel in vitro model of inner ear organogenesis that can be used to gain deeper insight into inner ear development and disorder.

Koordinierte Phosphorylierung der C-terminale Domäne von RNA Polymerase II (RNAPII) ist essentiell für eine effiziente Kupplung von naszierender RNA Synthese und co-transkriptionalem RNA Prozessierens. Zirkuläre RNAs (circRNAs) sind eine neue Klasse von RNA Molekülen mit hoher Prävalenz in neuronalen Zelltypen. Die Biogenese von circRNAs ist noch ungeklärt, insbesondere die Frage warum das Intron upstream der circRNA während der Transkription des circRNA Exons zurückbehalten wird um Rück-Spleißen zu ermöglichen. Verschiede Belege suggerieren, dass unzulängliche Rekrutierung des Spleiceosoms zur circRNA Formation führen kann. In dieser Arbeit untersuche ich die Mechanismen die zu Defekten in der Erkennung und des Spleißens des Introns upstream der circRNA führen. Mit diesem Ziel erfasste ich die genomweite Verteilung von chromatinassoziierter RNAPII mit verschiedenen Phosphorylierungen, sowie Spleißfaktoren und Transkriptionsreglern mittels ChIP-seq in neuronaler Differenzierung von murinen embryonalen Stammzellen zu dopaminergen und Motoneuronen. Während der gesamten Differenzierung, aber insbesondere in den differenzieren Neuronen, konnten circRNAs detektiert werden. In meiner Arbeit finde ich, dass circRNAs detektiert werden, wenn Gene hohe Levels an mRNA exprimieren und, dass die Produktion von circRNA mit einer Dysbalance zwischen dem Laden der RNA-Polymerase II auf die DNA und dem Rekruitieren der Splice-Maschinerie zusammen hängt. Um funktionell mit den Pausier-Mechanismen der RNA-Polymerase II zu interferieren, habe ich einen ''promotor-proximal-pausing'' Faktor depletiert. Dabei stellte ich fest, dass diese Depletion genügt, um die circRNA Levels in embryonalen Stamzellen zu erhöhen. Die Ergebnisse die in dieser Arbeit gezeigt werden, beschreiben die Beteiligung des Pausierens der RNA-Polymerase II and der Formierung von circRNAs. / Coordinated phosphorylation of RNA polymerase II (RNAPII) C-terminal domain is essential for efficient coupling of nascent RNA synthesis with co-transcriptional RNA processing events. Circular RNAs (circRNAs) are a novel class of RNAs whose biogenesis remains ill understood, namely why the upstream intron is not spliced before the circRNA-exon is fully transcribed. Indirect evidence suggests that altered spliceosome recruitment can lead to circRNA formation. To investigate the mechanisms that may be involved in deficient recognition and splicing of introns upstream of exons included in circRNAs, I mapped the chromatin occupancy of RNAPII phosphorylated forms, splicing factors, and transcription regulators by ChIP-seq during mouse ESC differentiation to dopaminergic and spinal motor neurons. CircRNAs are detected throughout differentiation, peaking in differentiated neurons, as expected. I found that circRNAs are detected when genes express high levels of mRNA, and that circRNA production is associated with an imbalance between RNAPII loading and recruitment of the splicing machinery. To mechanistically interfere with pausing mechanisms, I depleted an RNAPII promoter-proximal pausing factor, and found that it was sufficient to increase the formation of circRNAs in stem cells. Results shown in this work implicate RNAPII regulation mechanisms in the formation of circRNAs.

Indiana University-Purdue University Indianapolis (IUPUI) / Human induced pluripotent stem (iPS) cells have the unique ability to differentiate into 200 or so somatic cell types that make up the adult human being. The use of human iPS cells to study development and disease is a highly exciting and interdependent field that holds great promise in understanding and elucidating mechanisms behind cellular differentiation with future applications in drug screening and cell replacement studies for complex and currently incurable cellular degenerative disorders. The recent advent of iPS cell technology allows for the generation of patient-specific cell lines that enable us to model the progression of a disease phenotype in a human in vitro model. Differentiation of iPS cells toward the affected cell type provides an unlimited source of diseased cells for examination, and to further study the developmental progression of the disease in vitro, also called the “disease-in-a-dish” model. In this study, efforts were undertaken to recapitulate the differentiation of distinct retinal cell affected in two highly prevalent retinal diseases, Usher syndrome and glaucoma. Using a line of Type III Usher Syndrome patient derived iPS cells efforts were undertaken to develop such an approach as an effective in vitro model for studies of Usher Syndrome, the most commonly inherited disorder affecting both vision and hearing. Using existing lines of iPS cells, studies were also aimed at differentiation and characterization of the more complex retinal cell types, retinal ganglion cells (RGCs) and astrocytes, the cell types affected in glaucoma, a severe neurodegenerative disease of the retina leading to eventual irreversible blindness. Using a previously described protocol, the iPS cells were directed to differentiate toward a retinal fate through a step-wise process that proceeds through all of the major stages of neuroretinal development. The differentiation process was monitored for a period of 70 days for the differentiation of retinal cell types and 150 days for astrocyte development. The different stages of differentiation and the individually derived somatic cell types were characterized by the expression of developmentally associated transcription factors specific to each cell type. Further approaches were undertaken to characterize the morphological differences between RGCs and other neuroretinal cell types derived in the process. The results of this study successfully demonstrated that Usher syndrome patient derived iPS cells differentiated to the affected photoreceptors of Usher syndrome along with other mature retinal cell types, chronologically analogous to the development of the cell types in a mature human retina. This study also established a robust method for the in vitro derivation of RGCs and astrocytes from human iPS cells and provided novel methodologies and evidence to characterize these individual somatic cell types. Overall, this study provides a unique insight into the application of human pluripotent stem cell biology by establishing a novel platform for future studies of in vitro disease modeling of the retinal degenerative diseases: Usher syndrome and glaucoma. In downstream applications of this study, the disease relevant cell types derived from human iPS cells can be used as tools to further study disease progression, drug screening and cell replacement strategies.

Cardiovascular diseases are among the leading causes of death worldwide and particularly in the developed World. The search for new therapeutic approaches for improving the functions of the damaged heart is therefore a critical endeavour. Myocardial infarction, which can lead to heart failure, is associated with irreversible loss of functional cardiomyocytes. The loss of cardiomyocytes poses a major difficulty for treating the damaged heart since terminally differentiated cardiomyocytes have very limited regeneration potential. Currently, the only effective treatment for severe heart failure is heart transplantation but this option is limited by the acute shortage of donor hearts. The high incidence of heart diseases and the scarcity donor hearts underline the urgent need to find alternative therapeutic approaches for treating cardiovascular diseases. Pluripotent embryonic stem (ES) cells can differentiate into functional cardiomyocytes. Therefore the engraftment of ES cell-derived functional cardiomyocytes or cardiac progenitor cells into the damaged heart to regenerate healthy myocardial tissues may be used to treat damaged hearts. Stem cell-based therapy therefore holds a great potential as a very attractive alternative to heart transplant for treating heart failure and other cardiovascular diseases. A major obstacle to the realisation of stem cell-based therapy is the lack of donor cells and this in turn is due to the fact that, currently, the molecular mechanisms or the regulatory signal transduction mechanisms that are responsible for mediating ES cell differentiation into cardiomyocytes are not well understood. Overcoming this huge scientific challenge is absolutely necessary before the use of stem cell-derived cardiomyocytes to treat the damaged heart can become a reality. Therefore the aim of this thesis was to investigate the signal transduction pathways that are involved in the differentiation of stem cells into cardiomyocytes. The first objective was the establishment and use of cardiomyocyte differentiation models using H9c2 cells and P19 stem cells to accomplish the specific objectives of the thesis. The specific objectives of the thesis were, the investigation of the roles of (i) nitric oxide (ii) protein kinase C (PKC), (iii) p38 mitogen-activated protein kinase (p38 MAPK) (vi) phosphoinositide 3-kinase (PI3K) and (vi) nuclear factor-kappa B (NF-kB) signalling pathways in the differentiation of stem cells to cardiomyocytes and, more importantly, to identify where possible any points of convergence and potential cross-talk between pathways that may be critical for differentiation to occur. P19 cells were routinely cultured in alpha minimal essential medium (α-MEM) supplemented with 100 units/ml penicillin /100 μg/ml streptomycin and 10% foetal bovine serum (FBS). P19 cell differentiation was initiated by culturing the cells in microbiological plates in medium containing 0.8 % DMSO to form embryoid bodies (EB). This was followed by transfer of EBs to cell culture grade dishes after four days. H9c2 cells were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% FBS. Differentiation was initiated by incubating the cells in medium containing 1% FBS. In both models, when drugs were employed, they were added to cells for one hour prior to initiating differentiation. Cell monolayers were monitored daily over a period of 12 or 14 days. H9c2 cells were monitored for morphological changes and P19 cells were monitored for beating cardiomyocytes. Lysates were generated in parallel for western blot analysis of changes in cardiac myosin heavy chain (MHC), ventricular myosin chain light chain 1(MLC-1v) or troponin I (cTnI) using specific monoclonal antibodies. H9c2 cells cultured in 1% serum underwent differentiation as shown by the timedependent formation of myotubes, accompanied by a parallel increase in expression of both MHC and MLC-1v. These changes were however not apparent until 4 to 6 days after growth arrest and increased with time, reaching a peak at day 12 to 14. P19 stem cells cultured in DMSO containing medium differentiated as shown by the timedependent appearance of beating cardiomyocytes and this was accompanied by the expression of cTnI. The differentiation of both P19 stem cells and H9c2 into cardiomyocytes was blocked by the PI3K inhibitor LY294002, PKC inhibitor BIM-I and the p38 MAPK inhibitor SB2035800. However when LY294002, BIM-I or SB2035800 were added after the initiation of DMSO-induced P19 stem cell differentiation, each inhibitor failed to block the cell differentiation into beating cardiomyocytes. The NF-kB activation inhibitor, CAPE, blocked H9c2 cell differentiation into cardiomyocytes. Fast nitric oxide releasing donors (SIN-1 and NOC-5) markedly delayed the onset of differentiation of H9c2 cells into cardiomyocytes while slow nitric oxide releasing donors (SNAP and NOC-18) were less effective in delaying the onset of differentiation or long term differentiation of H9c2 cells into cardiomyocytes. Akt (protein kinase B) is the key downstream target of PI3K. Our cross-talk data also showed that PKC inhibition and p38 MAPK inhibition respectively enhanced and reduced the activation of Akt, as determined by the phosphorylation of Akt at serine residue 473. In conclusion, PKC, PI3K, p38 MAPK and NF-kB are relevant for the differentiation of stem cells into cardiomyocytes. Our data also show that the PKC, PI3K and p38 MAPK signalling pathways are activated as very early events during the differentiation of stem cells into cardiomyocytes. Our data also suggest that PKC may negatively regulate Akt activation while p38 MAPK inhibition inhibits Akt activation. Our fast NO releasing donor data suggest that nitric oxide may negatively regulate H9c2 cell differentiation.